Alao Michael Abel, Ogunbosi Babatunde Oluwatosin, Ibrahim Olayinka Rasheed, Oladokun Regina Eziuka, Lagunju Ikeoluwa Abiola
Department of Paediatrics, University College Hospital Ibadan, Oyo State, Nigeria.
College of Medicine University of Ibadan, Oyo State, Nigeria.
Niger Med J. 2022 Sep 12;63(3):248-258. doi: 10.60787/NMJ-63-3-46. eCollection 2022 May-Jun.
Vaccination has been described as the most critical tool to end the COVID-19 pandemic and to save lives and livelihoods. This study aimed to evaluate the spectrum of adverse events following immunization with the COVID-19 AstraZeneca/Oxford vaccine in Ibadan, southwestern Nigeria.
A cross-sectional study. Adults aged ≥ 18 years who had received the Astra-Zeneca/Oxford COVID-19 vaccine at selected COVID-19 vaccination centres across three Local Government Areas in Ibadan, SW Nigeria were interviewed by means of a structured questionnaire to determine the spectrum of adverse events following immunisation (AEFI).
We enrolled 369 adults; 179 males and 190 females, with a mean of age of 37.8 ±12.0 years. Three hundred and thirty-two (90.0%) of the subjects experienced one or more AEFI. Of the total AEFIs reported, the most frequent were headache 225 (21.1%), fatigue/tiredness 186 (17.4%), pain at the injection site 99 (9.3%) and myalgia 97(9.1%). Nine in ten (96.4%) of these AEFIs occurred within 48 hours post-vaccination. Higher severity of adverse events score (p=0.049) and multiple AEFIs (p=0.01) were associated with the first dose of the vaccine. There were severe AEFI in 1.2 % (95% CI: 0.3-.9.0%) of the respondents. Presumed or confirmed COVID 19 infection before vaccination increased the odds of AEFI (OR 7.0, 95% CI: 1.8-27.8).
Our study showed a high frequency of AEFI among recipients of the Astra Zenecca/Oxford vaccine in Ibadan. Majority of the AEFIs are mild and self-limiting. Previous infection with COVID-19 appears to increase the risk of AEFI.
疫苗接种被视为终结新冠疫情以及拯救生命和生计的最关键工具。本研究旨在评估在尼日利亚西南部伊巴丹接种阿斯利康/牛津新冠疫苗后不良事件的范围。
一项横断面研究。通过结构化问卷对年龄≥18岁、在尼日利亚西南部伊巴丹三个地方政府辖区的选定新冠疫苗接种中心接种了阿斯利康/牛津新冠疫苗的成年人进行访谈，以确定免疫接种后不良事件（AEFI）的范围。
我们纳入了369名成年人；179名男性和190名女性，平均年龄为37.8±12.0岁。332名（90.0%）受试者经历了一种或多种AEFI。在报告的所有AEFI中，最常见的是头痛225例（21.1%）、疲劳/疲倦186例（17.4%）、注射部位疼痛99例（9.3%）和肌痛97例（9.1%）。这些AEFI中有十分之九（96.4%）在接种疫苗后48小时内发生。不良事件评分的更高严重程度（p=0.049）和多种AEFI（p=0.01）与第一剂疫苗相关。1.2%（95%CI：0.3 - 9.0%）的受访者出现了严重AEFI。接种疫苗前假定或确诊的新冠病毒感染增加了AEFI的几率（OR 7.0，95%CI：1.8 - 27.8）。
我们的研究表明，在伊巴丹，阿斯利康/牛津疫苗接种者中AEFI的发生率很高。大多数AEFI是轻微的且具有自限性。先前感染新冠病毒似乎会增加AEFI的风险。
